



19th

# The novel oxazolidinone Radezolid (RX-1741) accumulates in THP-1 macrophages: comparative studies with linezolid and azithromycin


Sandrine Lemaire, Paul M. Tulkens, Françoise Van Bambeke

Unité de Pharmacologie cellulaire et moléculaire  
Louvain Drug Research Institute  
Université catholique de Louvain  
[<www.facm.ucl.ac.be>](http://www.facm.ucl.ac.be)



# From Linezolid to Radezolid


designed and  
developed by



linezolid

2 protonable aminated functions

radezolid





Heteroaryl substituant

Biaryl spacer

# Structure-based design of biaryl-oxazolidinones


- derived from observations made using the crystal structure of the 50S ribosomal unit complexed with known drugs and antibiotics
- combines the most important interactions defined by sparsomycin and linezolid into a single molecular design



additional interaction  
with A2602 and U2585  
of the 50S ribosomal binding site


Zhou et al., J. Bioorg. Med. Chem. Lett. (2008) 18:6179-83  
Skripkin et al. Antimicrob. Ag. Chemother. (2008) 52:3350-57

# Structure-based design of radezolid




# Aim of the study

- to investigate the cellular pharmacokinetics of **radezolid**
- to decipher the mechanisms of its cellular accumulation
  - in a model of THP-1 human macrophages
  - in comparison with **linezolid** and **azithromycin**



Oxazolidinone

- low accumulation
- cellular conc. ~ extracell. conc.




Macrolide

- dicationic amphiphile
- high accumulation by diffusion-segregation in acidic compartments


# Physico-chemical properties

drug	logP (Qikprop)	pKa <sub>1</sub>	pKa <sub>2</sub>
Linezolid	0.47		
Radezolid	0.7	6.8	9.4
Azithromycin	2.98	8.1	8.6

Similar lipophilicity



linezolid





radezolid

# Physico-chemical properties

drug	logP (Qikprop)	pKa <sub>1</sub>	pKa <sub>2</sub>
Linezolid	0.47		
Radezolid	0.7	6.8	9.4
Azithromycin	2.98	8.1	8.6


weak dibasic character



# General methodology



THP-1 cells  
growing in suspension



10<sup>6</sup> cells incubated with

- linezolid (250 mg/L),
- radezolid (50 mg/L, with a trace amount of <sup>14</sup>C-drug),
- azithromycin (10 mg/L)



- washed 3 X in ice-cold PBS
- collected by low-speed centrifugation



- resuspended in water

cell prot.  
(Lowry)


drug

scintillation counting

microbiological assay (*B. subtilis*)



accumulation calculated considering a cell volume of 5 µl/mg prot.

# Comparative accumulation level at equilibrium




in contrast to linezolid, radezolid accumulates  
in eucaryotic cells !

# Kinetics of accumulation and efflux




rapid accumulation; slower efflux

# Concentration - effect




non-saturable accumulation

# Role of multidrug transporters




# Influence of efflux pumps inhibitors




no influence of efflux pump inhibitors  
on radezolid accumulation/efflux

# Influence of ATP-depletion




no implication of energy-dependent processes  
in the accumulation of radezolid

# Importance of pH gradients




*De Duve. Biochem Pharmacol. (1974) 23:2495-531*

# How to collapse pH gradients ?




# How to collapse pH gradients ?




# Influence of pH gradients

influence of monensin  
on the accumulation of  
LZD, RX-1741, AZM




accumulation of RX-1741  
in culture media at different pH



radezolid accumulation reduced by 60-80 %  
when collapsing pH gradients


# Current model for cellular accumulation of radezolid




# Current model for cellular accumulation of radezolid

Accumulation by segregation - proton trapping in acidic compartments ?

- inhibited by monensin
- reduced in acidic medium
- efflux slower than influx



# Current model for cellular accumulation of radezolid



# Potential interest of cell accumulation

## ■ Pharmacokinetics ?


- ⇒ larger volume of distribution and tissue penetration
- ⇒ drug concentration at the site of infection

drug	Vd (mL/kg)		
	mouse	rat	dog
Linezolid	450	720	630
Radezolid	824	1239	975

RibX, data on file

## ■ Pharmacodynamics ?

- ⇒ activity on intracellular bacteria



O30 - Pharmacokinetics/Pharmacodynamics: clinical relevance



ECCMID

**Radezolid (RX-1741), a novel oxazolidinone, is active against intracellular *S. aureus*, *L. monocytogenes* and *L. pneumophila* phagocytosed by human THP-1 macrophages**

Sandrine Lemaire, Paul M. Tulkens, Françoise Van Bambeke

Unité de Pharmacologie cellulaire et moléculaire  
Louvain Drug Research Institute  
Université catholique de Louvain  
<[www.facm.ucl.ac.be](http://www.facm.ucl.ac.be)>

